Osteogenic biphasic calcium sulphate dihydrate/iron-modified alpha-tricalcium phosphate bone cement for spinal applications: in vivo study

Acta Biomater. 2010 Feb;6(2):607-16. doi: 10.1016/j.actbio.2009.07.010. Epub 2009 Jul 14.

Abstract

In this study, the biocompatibility and the osteogenic features of a new iron-modified alpha-tricalcium phosphate (IM/alpha-TCP) and calcium sulphate dihydrate (CSD) biphasic cement (IM/alpha-TCP/CSD-BC) have been investigated in terms of the in vivo cement resorption, bone tissue formation and host tissue response on sheep animal model. Histological evaluation performed on undecalcified cement-bone specimens assessed the in vivo behaviour. It has been shown that the new IM/alpha-TCP/CSD-BC has the ability to produce firm bone binding in vivo (i.e. bioactivity). Qualitative histology proved cement biocompatibility, osteoconduction and favourable resorption, mainly through a macrophage-mediated mechanism. The results showed that the new cements have biocompatible and osteogenic features of interest as possible cancellous bone replacement biomaterial for minimally invasive spinal surgery applications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biocompatible Materials
  • Bone Cements*
  • Calcium Phosphates / administration & dosage*
  • Calcium Phosphates / chemistry
  • Calcium Sulfate / administration & dosage*
  • Female
  • Iron / chemistry*
  • Sheep
  • Spine / surgery*

Substances

  • Biocompatible Materials
  • Bone Cements
  • Calcium Phosphates
  • Iron
  • tricalcium phosphate
  • Calcium Sulfate